

Andrew M Lowy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5796581/publications.pdf>

Version: 2024-02-01

82
papers

6,397
citations

117625
34
h-index

69250
77
g-index

84
all docs

84
docs citations

84
times ranked

10392
citing authors

#	ARTICLE	IF	CITATIONS
1	Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. <i>In Vivo</i> , 2022, 36, 57-62.	1.3	5
2	Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. <i>Gut and Liver</i> , 2022, 16, 625-636.	2.9	6
3	The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 2037.	3.7	7
4	Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. <i>Oncogene</i> , 2021, 40, 1957-1973.	5.9	22
5	Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1716-1723.	1.7	5
6	Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness. <i>Cancer Discovery</i> , 2021, 11, 1808-1825.	9.4	53
7	Tumor-penetrating therapy for $\alpha 5$ integrin-rich pancreas cancer. <i>Nature Communications</i> , 2021, 12, 1541.	12.8	37
8	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2021, 7, 421.	7.1	159
9	Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 279-287.	2.1	20
10	Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. <i>Cancer Cell</i> , 2021, 39, 678-693.e11.	16.8	91
11	Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal Origin. <i>JCO Precision Oncology</i> , 2021, 5, 1069-1072.	3.0	1
12	Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC. <i>Human Pathology</i> , 2021, 113, 104-110.	2.0	3
13	Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1003-1012.	0.8	21
14	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	7.0	22
15	Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC). <i>BMC Gastroenterology</i> , 2021, 21, 340.	2.0	1
16	Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2469-2482.	4.1	4
17	A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms. <i>Annals of Surgical Oncology</i> , 2021, 28, 4685-4694.	1.5	12
18	A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2100-2110.	7.0	17

#	ARTICLE	IF	CITATIONS
19	Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 ($\geq 1/2$ +) mutations: SWOG S2001.. Journal of Clinical Oncology, 2021, 39, TPS447-TPS447.	1.6	10
20	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	1.5	15
21	Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond. Cancers, 2021, 13, 4991.	3.7	10
22	Association of an acute pain service with postoperative outcomes following pancreaticoduodenectomy. Journal of Perioperative Practice, 2020, 30, 309-314.	0.5	2
23	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 134-146.	1.5	14
24	Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer, 2020, 23, 550-560.	5.3	21
25	Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases. Annals of Surgical Oncology, 2020, 27, 3259-3267.	1.5	14
26	Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. Journal of Experimental Medicine, 2020, 217, .	8.5	101
27	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. Journal of Surgical Oncology, 2020, 122, 980-985.	1.7	10
28	Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models. Journal of Visualized Experiments, 2020, , .	0.3	2
29	Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. Molecular Cancer Therapeutics, 2020, 19, 157-167.	4.1	21
30	Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. PLoS ONE, 2020, 15, e0243252.	2.5	2
31	Detection and Quantification of GPCR mRNA: An Assessment and Implications of Data from High-Content Methods. ACS Omega, 2019, 4, 17048-17059.	3.5	25
32	Obstruction-Free Survival Following Operative Intervention for Malignant Bowel Obstruction in Appendiceal Cancer. Annals of Surgical Oncology, 2019, 26, 3611-3617.	1.5	2
33	Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2019, 26, 2276-2284.	1.5	15
34	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Annals of Surgical Oncology, 2019, 26, 2234-2240.	1.5	16
35	Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. Annals of Surgical Oncology, 2019, 26, 1421-1427.	1.5	18
36	MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages. Oncogene, 2019, 38, 5599-5611.	5.9	29

#	ARTICLE	IF	CITATIONS
37	A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. <i>Cell</i> , 2019, 177, 572-586.e22.	28.9	107
38	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. <i>Genome Medicine</i> , 2019, 11, 8.	8.2	88
39	Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases. <i>Nature Communications</i> , 2019, 10, 5745.	12.8	45
40	Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. <i>American Journal of Cancer Research</i> , 2019, 9, 390-405.	1.4	7
41	Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC. <i>Annals of Surgical Oncology</i> , 2018, 25, 702-708.	1.5	33
42	Safety and Outcome Measures of First-in-Human Intraperitoneal \pm Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 716-721.	1.3	70
43	Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. <i>Journal of Surgical Research</i> , 2018, 221, 183-189.	1.6	22
44	GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. <i>FASEB Journal</i> , 2018, 32, 1170-1183.	0.5	83
45	Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 91-97.	1.5	22
46	Genomic Landscape of Appendiceal Neoplasms. <i>JCO Precision Oncology</i> , 2018, 2, 1-18.	3.0	23
47	E47 Governs the MYC-CDKN1B/p27 KIP1 -RB Network to Growth Arrest PDA Cells Independent of CDKN2A/p16 INK4A and Wild-Type p53. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 181-198.	4.5	14
48	Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 2400-2408.	1.5	46
49	GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic Targets. <i>Frontiers in Pharmacology</i> , 2018, 9, 431.	3.5	103
50	Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients. <i>World Journal of Surgical Oncology</i> , 2018, 16, 87.	1.9	3
51	GPR68, a proton sensing GPCR, mediates interaction of pancreatic cancer associated fibroblasts and cancer cells. <i>FASEB Journal</i> , 2018, 32, 695.2.	0.5	0
52	A Novel Inhibitor that Targets both p53-Dependent Apoptotic and Autophagy Pathways as a Pancreatic Cancer Therapeutic. <i>FASEB Journal</i> , 2018, 32, 836.16.	0.5	0
53	Hyaluronan-binding peptide for targeting peritoneal carcinomatosis. <i>Tumor Biology</i> , 2017, 39, 101042831770162.	1.8	21
54	Molecular Pathways: Targeting the Microenvironment of Liver Metastases. <i>Clinical Cancer Research</i> , 2017, 23, 6390-6399.	7.0	79

#	ARTICLE	IF	CITATIONS
55	Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. PLoS ONE, 2017, 12, e0189051.	2.5	31
56	Overinterpretation is common in pathological diagnosis of appendix cancer during patient referral for oncologic care. PLoS ONE, 2017, 12, e0179216.	2.5	18
57	A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer. Oncotarget, 2017, 8, 53154-53167.	1.8	14
58	Macrophage PI3K β Drives Pancreatic Ductal Adenocarcinoma Progression. Cancer Discovery, 2016, 6, 870-885.	9.4	235
59	Urokinase-controlled tumor penetrating peptide. Journal of Controlled Release, 2016, 232, 188-195.	9.9	46
60	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. JAMA Surgery, 2016, 151, e161137.	4.3	365
61	FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer, 2016, 16, 24.	2.6	44
62	Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature, 2016, 534, 407-411.	27.8	114
63	A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2016, 23, 1609-1617.	1.5	37
64	Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. Oncotarget, 2016, 7, 45959-45975.	1.8	24
65	PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget, 2016, 7, 28218-28234.	1.8	25
66	A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. Journal of Controlled Release, 2015, 212, 59-69.	9.9	62
67	Tumor Radiosensitization by Monomethyl Auristatin E: Mechanism of Action and Targeted Delivery. Cancer Research, 2015, 75, 1376-1387.	0.9	53
68	Tumor-Penetrating iRGD Peptide Inhibits Metastasis. Molecular Cancer Therapeutics, 2015, 14, 120-128.	4.1	99
69	Borderline resectable pancreatic cancer: Definitions and management. World Journal of Gastroenterology, 2014, 20, 10740.	3.3	135
70	A Hypusine \rightarrow eIF5A \rightarrow PEAK1 Switch Regulates the Pathogenesis of Pancreatic Cancer. Cancer Research, 2014, 74, 6671-6681.	0.9	80
71	Improved Perioperative Outcomes With Minimally Invasive Distal Pancreatectomy. JAMA Surgery, 2014, 149, 237.	4.3	81
72	A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nature Medicine, 2014, 20, 1340-1347.	30.7	188

#	ARTICLE	IF	CITATIONS
73	Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. <i>Genome Medicine</i> , 2014, 6, 43.	8.2	94
74	Pancreatic Adenocarcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1083-1093.	4.9	307
75	Therapeutic Advances in Pancreatic Cancer. <i>Gastroenterology</i> , 2013, 144, 1316-1326.	1.3	257
76	The RON Receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. <i>International Journal of Cancer</i> , 2012, 131, 1744-1754.	5.1	45
77	Development of an Orthotopic Model of Invasive Pancreatic Cancer in an Immunocompetent Murine Host. <i>Clinical Cancer Research</i> , 2010, 16, 3684-3695.	7.0	83
78	Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers. <i>Cancer Research</i> , 2010, 70, 1130-1140.	0.9	80
79	Preface. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, xv-xvi.	1.5	1
80	Neoadjuvant Therapy for Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 1600-1608.	1.7	39
81	The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression. <i>Cancer Research</i> , 2007, 67, 6075-6082.	0.9	108
82	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. <i>Cancer Cell</i> , 2003, 4, 437-450.	16.8	2,150